Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an adjuvant regimen) patients aged ≥ 70 years with advanced NSCLC.
Non Small Cell Lung Cancer
DRUG: ZD6474, Vandetanib|DRUG: Placebo to Match ZD6474, Vandetanib|DRUG: Gemcitabine
Progression Free Survival, Oct 2008- dec 2011
Overall Survival, Oct 2008- dec 2011|Overall Objective Response, Oct 2008- dec 2011|Duration of Response, Oct 2008- dec 2011|The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine, The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine is defined as the number of Adverse Events which includes any symptoms and/or Clinically Significant Laboratory or Vital Signs Abnormalities, and/or ECGs Changes, Oct 2008- Dec 2011
The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an adjuvant regimen) patients aged ≥ 70 years with advanced NSCLC.